Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pfizer has signed a definitive agreement to acquire Excaliard Pharmaceuticals, which will provide access to Excaliard's skin scarring drug, EXC 001.
Subscribe to our email newsletter
EXC 001 drug, co-developed by Excaliard and Isis Pharmaceuticals, is an antisense oligonucleotide that will hinder the process of fibrosis.
As per the deal, Pfizer will provide Excaliard an upfront payment and contingent payments.
EXC 001 has demonstrated data in Phase 2 study in reducing scar severity.
Pfizer plans to continue development of EXC 001 to treat patient groups suffering from skin scarring, once the acquisition is complete.
The transaction is expected to complete by the end of this year.